Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborator: National Institute on Aging (NIA)
• Treatments: Raloxifene Hydrochloride

Criteria

Inclusion Criteria:

• Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic)

• Mini Mental Status Exam score greater than 15/30

Exclusion Criteria:

• History of deep vein thrombosis or blot clots

• Diabetes

• Active heart disease or stroke

• Liver problems including hepatitis

• Severe vision or hearing problems

• Tobacco use